BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koskela K, Pelliniemi T, Pulkki K, Remes K. Treatment of Multiple Myeloma with All-Trans Retinoic Acid Alone and in Combination with Chemotherapy: a Phase I/II Trial. Leukemia & Lymphoma 2009;45:749-54. [DOI: 10.1080/10428190310001628158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Liu Z, Li T, Jiang K, Huang Q, Chen Y, Qian F. Induction of chemoresistance by all-trans retinoic acid via a noncanonical signaling in multiple myeloma cells. PLoS One 2014;9:e85571. [PMID: 24416428 DOI: 10.1371/journal.pone.0085571] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
2 Borges GSM, Lima FA, Carneiro G, Goulart GAC, Ferreira LAM. All-trans retinoic acid in anticancer therapy: how nanotechnology can enhance its efficacy and resolve its drawbacks. Expert Opin Drug Deliv 2021;:1-20. [PMID: 33896323 DOI: 10.1080/17425247.2021.1919619] [Reference Citation Analysis]
3 Malehmir M, Haghpanah V, Larijani B, Ahmadian S, Alimoghaddam K, Heshmat R, Ghavamzadeh A, Adabi K, Ghaffari SH. Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol 2012;348:260-9. [PMID: 21924320 DOI: 10.1016/j.mce.2011.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
4 Kalitin NN, Chernykh YB, Buravtsova IV. Comparative Analysis of Quantitative Parameters of Expression of the Retinoic Acid Nuclear Receptor RARα Gene and APE1/YB-1/MDR1 Pattern Genes in Patients with Newly Detected Multiple Myeloma. Bull Exp Biol Med 2017;164:90-4. [DOI: 10.1007/s10517-017-3931-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 2014;28:373-83. [PMID: 23760401 DOI: 10.1038/leu.2013.174] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 8.6] [Reference Citation Analysis]
6 Wang S, Tricot G, Shi L, Xiong W, Zeng Z, Xu H, Zangari M, Barlogie B, Shaughnessy JD Jr, Zhan F. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood 2009;114:600-7. [PMID: 19458357 DOI: 10.1182/blood-2008-12-194126] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
7 Marques Borges GS, Oliveira Ferencs MD, Mello Gomide Loures CD, Abdel-salam MA, Gontijo Evangelista FC, Sales CC, Reis da Silva PH, de Oliveira RB, Malachias Â, Yoshida MI, de Souza-fagundes EM, Paula Sabino AD, Fernandes C, Miranda Ferreira LA. Novel self-nanoemulsifying drug-delivery system enhances antileukemic properties of all- trans retinoic acid. Nanomedicine 2020;15:1471-86. [DOI: 10.2217/nnm-2020-0061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Sanda T. Transcription Factors as Therapeutic Targets in Lymphoid Malignancies. International Reviews of Immunology 2009;26:305-32. [DOI: 10.1080/08830180701655945] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 Sanda T, Kuwano T, Nakao S, Iida S, Ishida T, Komatsu H, Shudo K, Kuwano M, Ono M, Ueda R. Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis. Leukemia 2005;19:901-9. [PMID: 15843826 DOI: 10.1038/sj.leu.2403754] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
10 Fukui T, Kodera Y, Nishio K, Masuda N, Tamura T, Koizumi F. Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cells. Cancer Science 2009;100:1137-43. [DOI: 10.1111/j.1349-7006.2009.01155.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Ertesvåg Å, Naderi S, Blomhoff HK. Regulation of B cell proliferation and differentiation by retinoic acid. Seminars in Immunology 2009;21:36-41. [DOI: 10.1016/j.smim.2008.06.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
12 di Masi A, Leboffe L, De Marinis E, Pagano F, Cicconi L, Rochette-egly C, Lo-coco F, Ascenzi P, Nervi C. Retinoic acid receptors: From molecular mechanisms to cancer therapy. Molecular Aspects of Medicine 2015;41:1-115. [DOI: 10.1016/j.mam.2014.12.003] [Cited by in Crossref: 176] [Cited by in F6Publishing: 151] [Article Influence: 29.3] [Reference Citation Analysis]
13 Garattini E, Gianni' M, Terao M. Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents. Vitam Horm 2007;75:301-54. [PMID: 17368321 DOI: 10.1016/S0083-6729(06)75012-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
14 Abdelaal MR, Soror SH, Elnagar MR, Haffez H. Revealing the Potential Application of EC-Synthetic Retinoid Analogues in Anticancer Therapy. Molecules 2021;26:506. [PMID: 33477997 DOI: 10.3390/molecules26020506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]